- GR-MD-02 was safe and well tolerated in patients
- Galectin Therapeutics to host webcast, April 1, 8:30 a.m. EDT to discuss first cohort findings
- Second cohort of Phase 1 trial to begin enrollment in April
H.C. Wainwright reduced Galectin Thereapeutics' (GALT) stock rating to 'neutral' after the company's fatty liver disease drug failed in a phase II clinical trial.
Galectin Therapeutics' (GALT) stock rating was cut two notches to 'sell' at Roth Capital on Wednesday after the company's drug for fatty liver disease failed a clinical trial.
These stocks trading for less than $10 a share are within range of triggering big breakout trades. Here's how to trade them from here.